1.Artificial intelligence diagnosis based on breast ultrasound imaging.
Journal of Central South University(Medical Sciences) 2022;47(8):1009-1015
Breast cancer has now become the leading cancer in women. The development of breast ultrasound artificial intelligence (AI) diagnostic technology is conducive to promoting the precise diagnosis and treatment of breast cancer and alleviating the heavy medical burden due to the unbalanced regional development in China. In recent years, on the basis of improving diagnostic efficiency, AI technology has been continuously combined with various clinical application scenarios, thereby providing more comprehensive and reliable evidence-based suggestions for clinical decision-making. Although AI diagnostic technologies based on conventional breast ultrasound gray-scale images and cutting-edge technologies such as three-dimensional (3D) imaging and elastography have been developed to some extent, there are still technical pain points, diffusion difficulties and ethical dilemmas in the development of AI diagnostic technologies for breast ultrasound.
Artificial Intelligence
;
Breast/diagnostic imaging*
;
Breast Neoplasms/diagnostic imaging*
;
Elasticity Imaging Techniques/methods*
;
Female
;
Humans
;
Ultrasonography, Mammary/methods*
2.The cases of twins with sialidosis type 1
Dongchu LI ; Jianwen WANG ; Zhenzhen WANG ; Zihan REN ; Tiantian LAN ; Le CHANG ; Tao GU ; Guisheng CHEN
Chinese Journal of Neurology 2023;56(5):543-549
Sialidosis is a rare lysosomal storage disease caused by NEU1 gene mutation at 6p21.33. It is characterized by myoclonic, ataxia, epilepsy, and decreased vision. A pair of twins with sialidosis type 1 are reported to enrich clinicians ′ understanding of the disease, so as to improve the diagnosis and treatment. The proband was a 16-year-old male. The main symptom was intermittent limb involuntary trembling for 2 years, with paroxysmal loss of consciousness. Fundus examination showed cherry-red spots. His twin brother had similar symptoms, but the overall performance was mild. Whole exome sequencing results showed that both patients carried compound heterozygous mutations of c.239C>T (p.P80L) and c.803A>G (p.Y268C) in NEU1 gene, which were from their normal phenotype mother and father.
3.Recent advance of Marinesco-Sj?gren syndrome
Zihan REN ; Dongchu LI ; Bonian MA ; Zhenzhen WANG ; Tiantian LAN ; Zishan MA ; Zhifeng YANG ; Guisheng CHEN
Chinese Journal of Neuromedicine 2023;22(11):1183-1187
Marinesco-Sj?gren syndrome (MSS), also known as hereditary ataxia-dwarf-mental retardation syndrome, is a rare autosomal recessive ataxia syndrome. This article reviews the recent advance in clinic characteristics, pathogenic gene mutation sites, pathogenesis and clinic diagnosis and treatment of MSS, in order to improve clinicians' understanding of the disease and diagnosis and treatment level, and reduce the missed diagnosis and misdiagnosis of the disease.
4.Expert guidance on overall management of liver cancer during the COVID-19
Huichuan SUN ; Xinrong YANG ; Zhiping YAN ; Zhenggang REN ; Rong LIU ; Lan ZHANG ; Yang XU ; Yifeng HE ; Zihan ZHANG ; Jia FAN ; Jian ZHOU
Chinese Journal of Digestive Surgery 2022;21(5):557-563
The pandemic of Corona Virus Disease 2019 (COVID-19) continues, which shows the concentrated or sporadic cases in multiple places. Current COVID situation is still complex. During the COVID-19, routine diagnosis and treatment of liver cancer patients has been affected in different degrees. Under the premise of following the treatment guidelines, how to reduce the risk of infection of patients and medical staff, utilize limited medical resources to maximally ensure anti-tumor treatment and related emergency treatment, and help patients get through the epidemic period is a problem for liver oncologists. Thus, experts of liver cancer treatment related disciplines of Zhongshan Hospital, Fudan University have written the Expert guidance on overall management of liver cancer during the COVID-19, which aims to provide references for liver oncolo-gists to conduct clinical work safely and effectively under the epidemic prevention and control, and to help patients fight against the epidemic smoothly.
5.Effect of Shenqi Yiliu Prescription Combined with Cisplatin on Tumor in Hepatoma H22-bearing Mice Based on PTEN/PI3K/Akt Signaling Pathway
Xin FENG ; Yongqiang DUAN ; Min BAI ; Yuping YANG ; Liren CAO ; Junrui HU ; Yanhua SI ; Jing CHEN ; Zihan GONG ; Lan MA
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(3):96-103
ObjectiveTo investigate the tumor-suppressing effect of Shenqi Yiliu prescription combined with cisplatin in hepatoma H22-bearing mice based on the phosphatase and tensin homolog deleted on chromosome ten (PTEN)/phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) pathway. MethodH22-bearing mice were prepared and randomized into model group, cisplatin group, and cisplatin combined with high-, medium-, and low-dose Shenqi Yiliu prescription groups, with 10 mice in each group. Another 10 healthy mice were randomly selected as normal group. Shenqi Yiliu prescription was given by gavage with the high, medium, low dose of 54.06, 27.03, 13.515 g·kg-1·d-1, respectively, and cisplatin (2.5 mg·kg-1) was administered by intraperitoneal injection, twice a week. Normal group and model group received normal saline. After 13 days of treatment, mice were killed and the tumor inhibition rate was calculated. The pathomorphological changes of tumor were observed based on hematoxylin-eosin (HE) staining, and enzyme-linked immunosorbent assay (ELISA) and immunofluorescence method were used to detect the content of cyclin-dependent kinase inhibitor 1A (p21) and cyclin-dependent kinase inhibitor 1B (p27) in tumor tissue of mice. The levels of PTEN, PI3K and phosphorylated protein kinase B (p-Akt) in tumor tissue were measured by Western blot. ResultCompared with the model group, cisplatin alone and cisplatin in combination with the high-, medium-, and low-dose Shenqi Yiliu prescription decreased tumor mass (P<0.05), particularly the cisplatin in combination with the high-dose Shenqi Yiliu prescription. Necrosis of the tumor tissue was observed in each group, especially the cisplatin combined with high-dose Shenqi Yiliu prescription group. As compared with the model group, cisplatin alone and cisplatin in combination with the high-, medium-, and low-dose Shenqi Yiliu prescription raised the expression of p21, p27, and PTEN (P<0.05) and lowered the expression of PI3K and p-Akt (P<0.05), particularly the cisplatin in combination with high-dose Shenqi Yiliu prescription. ConclusionShenqi Yiliu prescription may regulate the expression of key molecules in PTEN/PI3K/Akt signaling pathway, thereby upregulating the expression of downstream proliferation inhibitors p21 and p27, further suppressing the tumor in H22-bearing mice, and enhancing the effect of chemotherapy.